HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population
Frontiers in Pharmacology · 11.10.2024 · 15
DOI: 10.3389/fphar.2024.1423636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.10.2024. Verfasst von Mohammed Dashti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, Kuwait. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study explores the frequency of human leukocyte antigen (HLA) genes, particularly HLA-B alleles, within the Kuwaiti population. We aim to identify alleles with known associations to adverse drug reactions (ADRs) based on existing literature. We focus on the HLA-B gene due to its well-documented associations with severe cutaneous adverse reactions and the extensive pharmacogenetic research supporting its clinical relevance.
Methods
We utilized the HLA-HD tool to extract, annotate, and analyse HLA-B alleles from the exome data of 561 Kuwaiti individuals, sequenced on the Illumina HiSeq platform. HLA typing was conducted using the HLA-HD tool with a reference panel from the IPD-IMGT/HLA database. The major HLA-B pharmacogenetic markers were obtained from the HLA Adverse Drug Reaction Database, focusing on alleles with significant ADR associations in published literature.
Results
The distribution of HLA-B alleles in the Kuwaiti population revealed that the most frequent alleles were HLA-B*50:01 (10.52%), HLA-B*51:01 (9.89%), HLA-B*08:01 (6.06%), HLA-B*52:01 (4.55%), HLA-B*18:01 (3.92%), and HLA-B*41:01 (3.65%). Notably, alleles HLA-B*13:01, HLA-B*13:02, HLA-B*15:02, HLA-B*15:13, HLA-B*35:02, HLA-B*35:05, HLA-B*38:01, HLA-B*40:02, HLA-B*44:03, HLA-B*51:01, HLA-B*57:01 and HLA-B*58:01 were identified with known associations to various ADRs. For example, HLA-B*51:01 was associated with clindamycin, phenobarbital, and phenytoin, and was found in 18% of individuals.
Conclusion
Our study enriches the regional genetic landscape by delineating HLA-B allele variations within Kuwait and across the Arabian Peninsula. This genetic insight, along with the identification of markers previously linked to drug hypersensitivity, provides a foundation for future pharmacogenetic research and potential personalized medicine strategies in the region.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait City, Kuwait.
- Narcotic and Psychotropic Department, Ministry of Interior, Farwaniya, Kuwait.
- College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Zitieren
APA
Dashti, M., Malik, M. Z., Al-Matrouk, A., Bhatti, S., Nizam, R., Jacob, S., Al-Mulla, F., & Thanaraj, T. A. (2024). HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1423636
Vancouver
Dashti M, Malik MZ, Al-Matrouk A, Bhatti S, Nizam R, Jacob S, et al. HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1423636
BibTeX
@article{Dashti2024,
author = {Dashti, Mohammed and Malik, Md Zubbair and Al-Matrouk, Abdullah and Bhatti, Saeeda and Nizam, Rasheeba and Jacob, Sindhu and Al-Mulla, Fahd and Thanaraj, Thangavel Alphonse},
title = {HLA-B allele frequencies and implications for pharmacogenetics in the Kuwaiti population},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1423636}
}
EUVIMED